A61K38/33 - CPC Classification Index

#1

20260137810

2026-05-21

GENE THERAPY VECTORS FOR THE EXPRESSION OF PREPRODYNORPHIN VARIANTS FOR THE TREATMENT OF EPILEPSY

#2

20240269230

2024-08-15

CYCLOTIDES IN COMBINATION WITH KAPPA OPIOID RECEPTOR LIGANDS FOR MS THERAPY

#3

20230077811

2023-03-16

ACTIVATION OF NEUROPEPTIDE RECEPTORS ON PLASMACYTOID DENDRITIC CELLS TO TREAT OR PREVENT OCULAR DISEASES ASSOCIATED WITH NEOVASCULARIZATION AND INFLAMMATION

#4

20220339239

2022-10-27

USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY

#5

20220241381

2022-08-04

Formulation Including a Combination of beta-Endorphin and Adrenocorticotropic Hormone

#6

20220168324

2022-06-02

CANCER THERAPY

#7

20220054595

2022-02-24

Formulation Including a Combination of beta-Endorphin and Adrenocorticotropic Hormone

#8

20210228724

2021-07-29

Bioconjugates of neuropeptides derivatives

#9

20210154272

2021-05-27

NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE

#10

20210101934

2021-04-08

Bovine adrenal medulla peptide 8-22 compounds and methods of use thereof for treating pain

#11

20210100878

2021-04-08

Formulation including a combination of beta-endorphin and adrenocorticotropic hormone

#12

20210046147

2021-02-18

COMBINATORIAL THERAPIES FOR THE TREATMENT OF NEOPLASIAS USING THE OPIOID GROWTH FACTOR RECEPTOR

#13

20190175626

2019-06-13

Cancer therapy

#14

20190111105

2019-04-18

Use of Melanocortins to Treat Insulin Sensitivity

#15

20190083455

2019-03-21

METHODS AND COMPOSITIONS FOR THE MODULATION OF BETA-ENDORPHIN LEVELS

#16

20190070301

2019-03-07

Activated polyoxazolines and conjugates and compositions comprising the same

#17

20190054150

2019-02-21

Melanocortins and methods of use thereof

#18

20180319842

2018-11-08

Compounds and methods for treating pain

#19

20180303899

2018-10-25

Use of Melanocortins to Treat Insulin Sensitivity

#20

20180221450

2018-08-09

Formulation Comprising A Stabilized Complex Of Corticotropin Releasing Hormone And Alpha-2 Macroglobulin

#21

20170290892

2017-10-12

POLYMERIC ENKEPHALIN PRODRUGS

#22

20170173171

2017-06-22

Activated polyoxazolines and conjugates and compositions comprising the same

#23

20160354429

2016-12-08

Use of melanocortins to treat insulin sensitivity

#24

20160206701

2016-07-21

Formulation comprising a stabilized complex of corticotropin releasing hormone and alpha-2 macroglobulin

#25

20160030454

2016-02-04

Cancer therapy

#26

20150366934

2015-12-24

Use of melanocortins to treat insulin sensitivity

#27

20150045719

2015-02-12

Combination of a MC1R receptor agonist and UVB for the treatment and/or prevention of pigmentation disorders

#28

20150018372

2015-01-15

Delta opioid receptor agonist compounds

#29

20140371147

2014-12-18

Combination of a prostaglandin receptor agonist and an MC1R receptor agonist for the treatment and/or prevention of pigmentation disorders

#30

20140315785

2014-10-23

Methods related to the treatment of neurodegenerative and inflammatory conditions

#31

20140127303

2014-05-08

Sustained-release composition containing peptides as active ingredient

#32

20140112961

2014-04-24

Methods and compositions for treating conditions related to lack of blood supply, shock, and neuronal injuries

#33

20140072530

2014-03-13

TREATMENT OF HIV

#34

20140031367

2014-01-30

Delta opioid receptor agonist compounds

#35

20130344102

2013-12-26

FORMULATION

#36

20130331324

2013-12-12

USE OF MELANOCORTINS TO TREAT DYSLIPIDEMIA

#37

20130259901

2013-10-03

Neuropeptide Y treatment of autoimmune disease

#38

20130203669

2013-08-08

MEDICAMENT

#39

20130084242

2013-04-04

Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor

#40

20130079287

2013-03-28

CAFFEOYLALPHANEOENDORPHIN PEPTIDE DERIVATIVE AND USE THEREOF AS ANTI-ITCHING AND ANTI-ATOPIC AGENTS

#41

20130053326

2013-02-28

Method of treating sexual dysfunctions with delta opioid receptor agonist compounds

#42

20120322736

2012-12-20

Methods for treatment of headaches by administration of oxytocin

#43

20120225816

2012-09-06

Pharmaceutical compositions of melanocortin receptor ligands

#44

20120220601

2012-08-30

Delta opioid receptor agonist compounds

#45

20120208745

2012-08-16

TREATMENT OF HIV

#46

20120142615

2012-06-07

Methods related to the treatment of neurodegenerative and inflammatory conditions

#47

20120135923

2012-05-31

Use of Melanocortins to Treat Dyslipidemia

#48

20120087956

2012-04-12

Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries

#49

20120028898

2012-02-02

Methods for treatment of headaches by administration of oxytocin

#50

20110250212

2011-10-13

Therapy procedure for drug delivery for trigeminal pain

#51

20110245149

2011-10-06

Methods to prevent and treat diseases

#52

20110150769

2011-06-23

IDENTIFICATION AND USE OF COMPOUNDS FOR TREATING PERSISTENT PAIN

#53

20110123437

2011-05-26

COMBINATORIAL THERAPIES FOR THE TREATMENT OF NEOPLASIAS USING THE OPIOID GROWTH FACTOR RECEPTOR

#54

20110112032

2011-05-12

Regulation of Brain Natriuretic Peptide and Catecholamines for the Treatment of Cardiovascular Diseases

#55

20100317578

2010-12-16

METHOD OF PROTECTING AGAINST STROKE THROUGH THE USE OF A DELTA OPIOID PEPTIDE

#56

20100311660

2010-12-09

Natriuretic peptide receptor-C agonists

#57

20100311647

2010-12-09

Use of melanocortins to treat insulin sensitivity

#58

20100273715

2010-10-28

Use of a peptide and an analgesic pharmaceutical agent

#59

20100273701

2010-10-28

USE OF SALUSIN BETA ALONE OR IN COMBINATION WITH OCTREOTIDE AS A THERAPEUTIC AGENT

#60

20100210562

2010-08-19

USE OF IL-1 RECEPTOR PEPTIDE, ALONE OR IN COMBINATION WITH D-ALA-GLN-OCTADECYL ESTER, AS A THERAPEUTIC AGENT

#61

20100210558

2010-08-19

MINIGASTRIN AS A THERAPEUTIC AGENT

#62

20100210556

2010-08-19

USE OF A PEPTIDE AS A THERAPEUTIC AGENT

#63

20100210536

2010-08-19

USE OF LEPTIN (22-56 ) AS A THERAPEUTIC AGENT

#64

20100184677

2010-07-22

USE OF THE HUMAN PANCREATIC POLYPEPTIDE AS A THERAPEUTIC AGENT

#65

20100173845

2010-07-08

USE OF FERTIRELIN AND DELTA-ENDORPHIN AS THERAPEUTIC AGENTS

#66

20100113347

2010-05-06

EXENATIDE AND DALARGIN-BASED MEDICINAL PREPARATION FOR TREATING PANCREATIC DIABETES

#67

20100080797

2010-04-01

THERAPY PROCEDURE FOR DRUG DELIVERY FOR TRIGEMINAL PAIN

#68

20100016209

2010-01-21

Methods of Reducing Side Effects in Cancer Therapy

#69

20100015147

2010-01-21

Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting GM1-ganglioside

#70

20090325878

2009-12-31

ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY

#71

20090318361

2009-12-24

Anti-hemorrhage medication pack

#72

20090317377

2009-12-24

Therapy procedure for drug delivery for trigeminal pain

#73

20090291900

2009-11-26

Methods for treatment of headaches by administration of oxytocin

#74

20090291060

2009-11-26

Treatment of HIV

#75

20090181880

2009-07-16

Methods for treatment of headaches by administration of oxytocin

#76

20080286315

2008-11-20

Methionine Enkephalin as an Adjuvant for Vaccine Immunizations

#77

20080261890

2008-10-23

Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions

#78

20080207500

2008-08-28

Medicament

#79

20080200563

2008-08-21

Use of Compounds Containing Thiol Groups as Efflux Pump Inhibitors

#80

20080146512

2008-06-19

Cyclin-dependent kinase inhibitors as targets for opiod growth factor treatment

#81

20080038199

2008-02-14

Methods related to the treatment of neurodegenerative and inflammatory conditions

#82

20080008694

2008-01-10

METHODS TO PREVENT AND TREAT DISEASES

#83

20070173515

2007-07-26

DELTA OPIOID RECEPTOR AGONIST COMPOUNDS

#84

20070172517

2007-07-26

Compositions capable of facilitation penetration across a biological barrier

#85

20070154534

2007-07-05

Use of secretin in the treatment of schizophrenia

#86

20070142287

2007-06-21

Compositions And Methods For Treatment Of Cancer

#87

20070093420

2007-04-26

Therapy procedure for drug delivery for trigeminal pain

#88

20070060501

2007-03-15

Methods and therapies for potentiating a therapeutic action of an opioid receptor agonist and inhibiting and/or reversing tolerance to opioid receptor agonists

#89

20070054843

2007-03-08

Methods for treatment of headaches by administration of oxytocin

#90

20070053838

2007-03-08

Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor

#91

20070010451

2007-01-11

Method of protecting cells against damage and pharmaceutical composition comprising leumorphin

#92

20060270592

2006-11-30

Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions

#93

20060222717

2006-10-05

Agent for preventing and curing pathologies states associated with endorphin deficiency in organism

#94

20060148679

2006-07-06

Glycosolated enkephalin agents

#95

20060099193

2006-05-11

Methods and materials for suppressing pain

#96

20060058222

2006-03-16

Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders

#97

20060034941

2006-02-16

Organ preconditioning, arrest, protection, preservation and recovery

#98

20060029678

2006-02-09

Process for the production of implants

#99

20050191241

2005-09-01

Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor

#100

20050181974

2005-08-18

Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists

#101

20050130893

2005-06-16

Use of opioids in prevention of and recovery from a stress-induced crash in blood pressure

#102

20050026842

2005-02-03

Compositions of Alpha3beta4 Receptor antagonists and opioid agonist analgesics

#103

20050014696

2005-01-20

Additive cytoprotective effects of two bioactive regions of pro-opiomelanocortin hormone